Bio-Rad is traded on the New York Stock Exchange: BIO and BIOb
Class B Common Stock (BIOb) was originally issued as "founder's stock" but was replaced by Class A (BIO) Common Stock as the "trading stock."
Due to the different trading volume of each class of stock, the price may be different, depending on the date and time that the individual class of stock last traded. The two classes of stock have different voting rights as well.
The holders of Class A Common Stock, voting as a separate class, are entitled to elect two directors. The holders of Class B Common Stock, also voting as a separate class, are entitled to elect the other five directors.
Each share of Class A Common Stock is entitled to one-tenth of a vote and each share of Class B Common Stock is entitled to one vote, except in the election of directors and any other matter requiring the vote of one or both classes of Common Stock.
No.
No. Bio-Rad does not have a direct purchase plan. Please contact your stockbroker to purchase Bio-Rad shares.
There have been a total of nine splits to date:
Please contact our transfer agent:
Computershare c/o Shareholder Services 462 South 4th Street, Suite 1600 Louisville, KY 40202 800-962-4284 www.computershare.com
Bio-Rad held its initial public offering in 1966. The company's state of incorporation is Delaware.
Bio-Rad 2021 sales by region were 42% Americas, 25% Asia Pacific, and 33% Europe, Middle East, Africa
KPMG LLP
Citi – Patrick Donnelly Credit Suisse – Dan Leonard Jefferies – Brandon Couillard Nephron Research – Jack Meehan RBC - Conor McNamara